Reviewed by Michael Gill, B. Sc.
9 Xofigo Clinical Trials Near Me
Top Cities for Xofigo Clinical Trials
Image of Saint Louis in Missouri.
Saint Louis
8Active Trials
Washington University School of MedicineTop Active Site
Image of Sacramento in California.
Sacramento
4Active Trials
University of California Davis Comprehensive Cancer CenterTop Active Site
Xofigo Clinical Trials by Phase of Trial
Phase 1 Xofigo Clinical Trials
1Active Xofigo Clinical Trials
1Number of Unique Treatments
0Number of Active Locations
Most Recent Xofigo Clinical Trials

What Are Xofigo Clinical Trials?

Xofigo is a form of radiation therapy, delivered intravenously, to treat prostate cancer. Xofigo clinical trials are necessary research studies that investigate the performance, safety, and effectiveness of this novel treatment in humans. Such studies are crucial for doctors and researchers in the development of new, and improvement of previous, forms of cancer treatments.

Xofigo is a new treatment for prostate cancer that is still in the stage of being tested in clinical trials. Xofigo is a radioactive drug that is injected into the body. It goes to the bones and helps kill cancer cells. Xofigo clinical trials are being done to learn if Xofigo is safe and effective in treating prostate cancer.

Why Is Xofigo Being Studied in Clinical Trials?

Prostate cancer cells depend on testosterone to grow and spread. The standard treatment paradigm for this type of cancer is hormone therapy that lowers overall testosterone levels in the body. Castration-resistant prostate cancer occurs when the prostate cancer continues to grow, even when testosterone levels have been significantly reduced.

The Food and Drug Administration (FDA) has approved castration-resistant prostate cancer. However, the FDA has mainly allowed Xofigo to be used in clinical trials. Clinical trials are currently being performed to see the long-term effects of Xofigo and to find out what side effects it may cause.

Xofigo is being studied because it may help men with prostate cancer that has spread to the bones. The drug may help relieve pain and other symptoms caused by cancer in the bones. It has also been beneficial in different types of cancer, such as breast cancer.

With further testing in clinical trials, doctors hope to learn more about the side effects of Xofigo and how well it works in treating prostate cancer. The FDA may approve Xofigo as a new breast and prostate cancer treatment if future tests go well.

How Does Xofigo Work?

Xofigo is a type of radiation therapy. It uses drugs that contain radioactive atoms. These atoms release radiation as they decay. The radiation kills cancer cells or stops them from growing.

Xofigo is injected into a vein and travels through the bloodstream to the bones. Once it reaches the bones, it gives off radiation to kill cancerous cells. The radiation does not stay in the body for very long and will eventually leave the body through urine.

What Are Some of The Breakthrough Clinical Trials Involving Xofigo?

Some of the breakthrough trials for Xofigo include:

2021: This study showed prolonged survival in patients with metastatic castration prostate cancer. With Metastatic castration-resistance prostate cancer being fatal, this was a significant breakthrough.

2019: A study published in the New England Journal of Medicine showed that men with metastatic hormone-sensitive prostate cancer who received xofigo and androgen deprivation therapy (ADT) had a longer life expectancy without the disease progressing compared to men who received ADT alone.

Other ongoing clinical trials test different ways to use Xofigo, such as combining it with other treatments.

Who Are The Key Opinion Leaders On Xofigo Clinical Trial Research?

Dr. Gabriel Hortobagyi, MD, from the University of Texas MD Anderson Cancer Center. His research focuses on xofigo clinical trials and their efficacy in patients with metastatic breast cancer.

Dr. Howard Scher, MD, from Memorial Sloan-Kettering Cancer Center. His research focuses on xofigo clinical trials and their efficacy in patients with metastatic prostate cancer.

Dr. Scott Kopetz, MD, from the University of Texas MD Anderson Cancer Center. He is the principle investigator of a xofigo clinical trial. His research focuses on xofigo in patients with metastatic colorectal cancer.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: October 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Bade RM, Schehr JL, Emamekhoo H, Gibbs BK, Rodems TS, Mannino MC, Desotelle JA, Heninger E, Stahlfeld CN, Sperger JM, Singh A, Wolfe SK, Niles DJ, Arafat W, Steinharter JA, Jason Abel E, Beebe DJ, Wei XX, McKay RR, Choueri TK, Lang JM. Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma. Mol Oncol. 2021 Sep;15(9):2330-2344. doi: 10.1002/1878-0261.12931. Epub 2021 Mar 3. https://pubmed.ncbi.nlm.nih.gov/336049992 Shore N, Higano CS, George DJ, Sternberg CN, Saad F, Tombal B, Miller K, Kalinovsky J, Jiao X, Tangirala K, Sartor O. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020 Dec;23(4):680-688. doi: 10.1038/s41391-020-0236-0. Epub 2020 May 13. https://pubmed.ncbi.nlm.nih.gov/324048683 Matsubara N, Kimura G, Uemura H, Uemura H, Nakamura M, Nagamori S, Mizokami A, Kikukawa H, Hosono M, Kinuya S, Krissel H, Siegel J, Kakehi Y. A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study. Int J Clin Oncol. 2020 Apr;25(4):720-731. doi: 10.1007/s10147-019-01589-6. Epub 2019 Dec 10. https://pubmed.ncbi.nlm.nih.gov/318231524 Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6. Erratum in: Lancet Oncol. 2019 Oct;20(10):e559. https://pubmed.ncbi.nlm.nih.gov/30738780